Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20788712 | 1.00 | ALDH1A1 (0.52) | ALDH1A1GAAAAK1KDM4EHPGD | |
| SCHEMBL29971413 | 1.00 | ALDH1A1 (0.52) | ALDH1A1GAAAAK1KDM4EHPGD | |
| SCHEMBL19585926 | 0.89 | AAK1 (0.52) | ALDH1A1GAAAAK1KDM4ECTSS | |
| SCHEMBL19585925 | 0.89 | AAK1 (0.52) | ALDH1A1GAAAAK1KDM4ECTSS | |
| SCHEMBL19032231 | 0.85 | ALDH1A1 (0.58) | ALDH1A1GAAAAK1MAPTLMNA | |
| SCHEMBL31012013 | 0.85 | ALDH1A1 (0.58) | ALDH1A1GAAAAK1MAPTLMNA | |
| SCHEMBL24638289 | 0.84 | AAK1 (0.54) | ALDH1A1AAK1MAPTLMNASMN1; SMN2 | |
| SCHEMBL30048937 | 0.84 | AAK1 (0.54) | ALDH1A1AAK1MAPTLMNASMN1; SMN2 | |
| SCHEMBL31174517 | 0.83 | AAK1 (0.57) | GAAAAK1KDM4EHPGDGLA | |
| SCHEMBL25904134 | 0.83 | KDM4E (0.59) | ALDH1A1GAAKDM4EHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113453679-A | Targeted protein degradation | C4医药公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | ALDH1A1 2438/4885GAA 1681/4885AAK1 3046/4885 |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | ALDH1A1 2438/4885GAA 1681/4885AAK1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.